PreHevbrio global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023



Continued execution across earlier-stage pipeline, including:


Initiation of Phase 2b study of VBI-1901 in...

Related Keywords

Wuhan , Hubei , China , Cambridge , Cambridgeshire , United Kingdom , United States , Gilboa , Ha Afon , Israel , Rehovot , Hamerkaz , Japan , Ottawa , Ontario , Canada , Massachusetts , Canadian , Israeli , Brii Biosciences Bio , Jeff Baxter , Prehevbrio Prehevbri , Brii Bio , European Union Economic Area , Delivery Networks Idns , Association With , Nasdaq , Reconciliations Of The Company , Key Program Achievements , Coalition For Epidemic Preparedness Innovations , Foreign Exchange Loss , Vaccines Inc , Technology Platform , Company Quarterly Reports On Form , European Union , Agenus Inc , Projected Upcoming , Integrated Delivery Networks , Brii Biosciences , Asia Pacific , Expert Review , Liver Meeting , Orphan Drug Designated , Individualized Screening Trial , Innovative Glioblastoma Therapy , Multivalent Pan Coronavirus Vaccine , Epidemic Preparedness Innovations , Cash Used , Operating Activities , Net Loss Per Share , Excluding Impairment Charges , Canadian Dollars , New Israeli Shekel , Net Loss , Foreign Exchange , Months Ended September , European Economic Area , Safety Information , Full Prescribing , Immune Response After , Private Securities Litigation Reform Act , Nasdaq Capital Market , Annual Report , Quarterly Reports , Consolidated Statement , Thousands Except Share , Per Share Amounts , Loss Available , Markets ,